期刊
CURRENT CARDIOLOGY REPORTS
卷 24, 期 10, 页码 1327-1335出版社
SPRINGER
DOI: 10.1007/s11886-022-01748-8
关键词
Influenza vaccine; Cardiovascular disease prevention; Myocardial infarction; IAMI; COVID vaccine; Cardiovascular events
资金
- Amato Fund in Women's Cardiovascular Health Research at Johns Hopkins University
Influenza infection is a well-established cause of cardiovascular disease (CVD) and CV mortality, but influenza vaccination has been shown to reduce major adverse cardiovascular events (MACE) and CV mortality. Recent studies, including the IAMI trial, have confirmed the safety and efficacy of influenza vaccination in reducing MACE and CV mortality in patients with recent myocardial infarction. The findings suggest that influenza vaccination should be strongly encouraged in all patients with CVD for secondary prevention.
Purpose of Review Influenza infection is a significant, well-established cause of cardiovascular disease (CVD) and CV mortality. Influenza vaccination has been shown to reduce major adverse cardiovascular events (MACE) and CV mortality. Therefore, major society guidelines have given a strong recommendation for its use in patients with established CVD or high risk for CVD. Nevertheless, influenza vaccination remains underutilized. Historically, influenza vaccination is administered to stable outpatients. Until recently, the safety and efficacy of influenza vaccination among patients with acute myocardial infarction (MI) had not been established. Recent Findings The recently published Influenza Vaccination after Myocardial Infarction (IAMI) trial showed that influenza vaccination within 72 h of hospitalization for MI led to a significant 28% reduction in MACE and a 41% reduction in CV mortality, without any excess in serious adverse events. Additionally, we newly performed an updated meta-analysis of randomized clinical trials (RCTs) including IAMI and the recent Influenza Vaccine to Prevent Adverse Vascular Events (IVVE) trial. In pooled analysis of 8 RCTs with a total of 14,420 patients, influenza vaccine, as compared with control/placebo, was associated with significantly lower risk of MACE at follow-up [RR 0.75 (95%CI 0.57-0.97), I-2 56%]. The recent IAMI trial showed that influenza vaccination in patients with recent MI is safe and efficacious at reducing CV morbidity and mortality. Our updated meta-analysis confirms a 25% reduction in MACE. The influenza vaccine should be strongly encouraged in all patients with CVD and incorporated as an essential facet of post-MI care and secondary CVD prevention.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据